Table 3: Overall sample sexual and reproductive health status.
|
|
Tertiary
Institution |
C&G
NGO |
Factory |
SRH NGO |
||||
|
Sex n |
|
Female
59 |
Male 50 |
Female
56 |
Male 7 |
Female
4 |
Male 19 |
Male 2 |
|
Ever pregnant/partner pregnant n (%) |
|
23 (40.0) |
17 (34.0) |
49 (87.6) |
5(71.4) |
4 (100) |
18 (94.8) |
2 (100) |
|
Last pregnancy unplanned n (%) |
|
22 (95.7) |
14 (82.4) |
37 (75.1) |
2 (40) |
3 (75) |
17(94.4) |
2 (100) |
|
Ever tested for HIV n (%) |
|
59 (100) |
42(84.0) |
56 (100) |
7(100) |
4 (100) |
19 (100) |
2 (100) |
|
Current sexual relationship status n (%) |
One regular/primary partner |
53 (89.8) |
17 (34.0) |
22 (39.3)*^ |
2 (28.7) |
4 (100) |
9 (47.4) |
1 (50) |
|
Casual partners only |
1 (1.7) |
12 (24.0) |
3 (5.46)*^ |
1 (14.3) |
0 (0.0) |
0 (0.0) |
1 (50) |
|
|
Both regular and casual partners |
5 (8.5) |
21(42.0) |
29 (54.8)*^ |
4 (57.1) |
0 (0.0) |
10(52.6) |
0 (0.0) |
|
|
Family planning methods used last 3 months† n (%) |
Norethisterone Enanthate
(NET-EN) injectable |
4 (6.8) |
5 (10.0)ⁱ |
3 (5.4) |
0 (0.0) |
0 (0.0) |
1 (5.3) 2(10.5)ⁱ |
0 (0.0) |
|
Depo-Provera®
(DMPA) injectable |
6 (10.2) |
5 (10.0) 5 (10.0)ⁱ |
14 (25) |
3 (42.9) |
1 (25.0) |
3 (15.8) 1 (5.3)ⁱ |
1 (50.0) |
|
|
Contraceptive pills combined |
3 (5.1) |
2 (4.0) 3 (6.0)ⁱ |
0 (0.0) |
2 (28.6)ⁱ |
1 (25.0) |
1 (5.3) |
0 (0.0) |
|
|
Progestogen-only
contraceptive pills |
0 (0.0) |
4 (8.0)ⁱ |
2 (3.6) |
1 (14.3)ⁱ |
0 (0.0) |
0 (0.0) |
0 (0.0) |
|
|
IUD |
1 (1.7) |
4 (8.0)ⁱ |
0 (0.0) |
1 (14.3)ⁱ |
0 (0.0) |
0 (0.0) |
0 (0.0) |
|
|
Implants |
0 (0.0) |
2 (4.0) 1 (2.0)ⁱ |
0 (0.0) |
1 (14.3)ⁱ |
0 (0.0) |
1 (5.3) |
0 (0.0) |
|
|
Sterilisation |
1 (1.7) |
2 (4.0) |
6 (10.8) |
0 (0.0) |
0 (0.0) |
0 (0.0) |
0 (0.0) |
|
|
Withdrawal |
21 (35.6) |
15 (30.0) |
13 (23.2) |
4 (57.1) |
2 (50) |
8 (42.1) |
1 (50) |
|
|
Emergency contraception(3 months) |
14 (23.7) |
13 (26.0) |
5 (9.0) |
0 (0.0) |
0 (0.0) |
2 (10.5) |
0 (0.0) |
|
|
LAM breastfeeding |
0 (0.0) |
0 (0.0) |
2 (3.6) |
0 (0.0) |
0 (0.0) |
2 (10.5) |
0 (0.0) |
|
|
Fertility awareness |
4 (6.9) |
5 (10.0) |
0 (0.0) |
0 (0.0) |
0 (0.0) |
2 (10.5) |
0 (0.0) |
|
|
Other FP method |
0 (0.0) |
0 (0.0) |
0 (0.0) |
0 (0.0) |
0 (0.0) |
0 (0.0) |
0 (0.0) |
|
|
Female condomuse n (%) |
Ever used FCs |
9
(15.3) |
7
(14) |
38
(67.9) |
4
(57.1) |
2
(50) |
4
(21.1) |
0
(0.0) |
|
|
FC use in last 3 months |
5
(8.5) |
2
(4) |
28
(50) |
1
(14.3) |
0
(0.0) |
1
(5.3) |
0
(0.0) |
|
Male condomuse n (%) |
Ever used MCs |
59
(100) |
50
(100) |
56
(100) |
7
(100) |
4
(100) |
19
(100) |
2
(100) |
|
|
MC use in last 3 months |
56
(94.9) |
49
(98) |
55
(98.2) |
6
(85.7) |
3
(75) |
17
(89.5) |
2
(100) |
|
Condom
at last sex n (%) |
No
condom |
12
(20.3) |
10
(20) |
7
(12.5)* |
3
(42.9) |
2
(50) |
6
(34.6) |
1(50) |
|
|
Male
condom |
46(78.0) |
40
(80) |
45
(80.4)* |
4
(57.1) |
2(50) |
13(68.4) |
1(50) |
|
|
Female
condom |
1
(1.7) |
0
(0.0) |
3
(5.4)* |
0
(0.0) |
0
(0.0) |
0
(0.0) |
0
(0.0) |
*Missing
data. ^ n = 1 other partner specified as “clients.” ⁱSome males did not know their partner’s FP method. †Multiple response item.